| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:citatuzumab
CAS:896731-82-1
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13745
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Conatumumab
CAS:896731-82-1
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Conatumumab
CAS:896731-82-1
Purity:95% Package:1mg;1g;100g
|
citatuzumab manufacturers
- Conatumumab
-
- $378.00
-
2026-07-03
- CAS:896731-82-1
- Purity: > 95%
- Supply Ability: 10g
|
| | citatuzumab Basic information |
| Product Name: | citatuzumab | | Synonyms: | citatuzumab;Conatumumab;Research Grade Conatumumab(DHA29103);TRAIL-R2 mAb|||AMG 655;Research Grade Citatuzumab;Research Grade Conatumumab;Conatumumab (anti-TNFRSF10B) | | CAS: | 896731-82-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![citatuzumab Structure]() |
| | citatuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | citatuzumab Usage And Synthesis |
| Uses | Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
[1][2][3]. | | in vivo | Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2].
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft[2].
| Animal Model: | Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2] | | Dosage: | 0, 0.1, 0.3, 1, 3, 10, 30, 100 μg | | Administration: | Intraperitoneal injection (i.p.), twice weekly. | | Result: | Dose-dependently inhibited tumor growth.
Induced caspase-3 activation in tumors (determined by IHC).
|
| | References | [1] Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. DOI:10.1158/1078-0432.CCR-10-0631
[2] Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31. DOI:10.4161/cbt.9.8.11264 |
| | citatuzumab Preparation Products And Raw materials |
|